In this article, we will be taking a look at the 10 cheap biotech stocks to invest in now.
Biotech Stocks Face Uncertainty Despite Interest Rate Cuts
Biotechnology stocks are among the most volatile in the market due to their high risk. The outcomes of FDA clinical trials and the effectiveness of their therapies in the real world might cause significant fluctuations in their pricing. The introduction of COVID-19 vaccinations in 2020 caused the biotech industry to soar to prominence. As Big Pharma started investing in acquisitions, investor interest increased in late 2023 and early 2024. But the momentum faded, and for months, biotech stocks did not move. Few M&A transactions and initial public offerings (IPOs) broke the otherwise quiet period in the second quarter, which saw a steep fall in biopharma deal activity. This slowdown followed a thriving first quarter in which pharmaceutical companies began using their enormous cash reserves for acquisitions.
However, the reaction was unexpectedly subdued, even though the industry expected a drop in the federal interest rate. The Federal Reserve lowered interest rates by half a percentage point earlier in September, which was a bigger drop than anticipated. Although it’s a good step, Mizuho Securities analyst Jared Holz thinks it’s unlikely that there will be a spike in fundraising, M&A transactions, or IPOs. A lot of biotech businesses have canceled programs and made large layoffs to save money in an attempt to survive in volatile markets. Holz thinks it’s hard to gauge the impact, even though the tax drop would inspire some scientific endeavors to be revived. However, the analyst noted that small-cap stocks have experienced “a bit more momentum” since the rate cut, which is encouraging for the biotech industry:
“When I look at biotech, I just view it as a nichey, highly academic kind of component of small-cap equities. If small-cap stocks continue to trade well, biotech will probably do fine. And if not, then maybe there’s a point in which there’s a little bit of stagnation in terms of the index.”
Holz added that the recent rate decline has drawn more attention, but he clarified that the notion that interest rates might forecast the success of biotech companies is still relatively new. Interest rates have minimal impact on biotech equities before 2020. The pandemic changed the environment as investors flocked to the sector and significant sums of money poured into businesses that specialized in medicines.
Biotech Market Poised for Trillion-Dollar Growth Despite High Risks
Precedence Research projects that the worldwide biotech market will reach a valuation of $4.61 trillion by 2034, growing at a compound annual growth rate of 11.5%. Favorable government regulations, more investment, the need for synthetic biology, and a rise in chronic illnesses like cancer, heart disease, and high blood pressure are all predicted to contribute to this growth. The market is expanding as a result of government measures to improve reimbursement policies and update laws. Global drug spending is expected to reach $2.30 trillion by 2028, with a compound annual growth rate (CAGR) of 5% to 8%, according to IQVIA. Treatments for obesity and cancer are anticipated to be the main drivers of this growth, whereas immunology spending may decline as biosimilars become available. By 2028, biotech is expected to reach $892 billion, or 39% of total spending, with cell and gene therapies seeing the fastest rise.
Particularly, the U.S. biotechnology industry was valued at $246.18 billion in 2023 and is expected to increase at a compound annual growth rate (CAGR) of 11.6% from 2024 to 2034 to reach approximately $830.31 billion. North America had a revenue share of 37.79%, while Asia Pacific had a revenue proportion of 23.99%. In 2023, the biopharmacy segment had a 41.73% revenue share by application, while the bioindustry application segment contributed 24.33% of overall revenue.
Despite its potential, investment in biotech startups has several dangers. The industry has a high failure rate, with 90% of initiatives failing and drug development taking more than ten years. Companies that fail to meet clinical trial endpoints or lack sufficient funds before product launch may face bankruptcy. Biotech is often regarded as a “high-risk, high-reward” investment because of its substantial dangers and growth potential. Given this, we will take a look at some of the best cheap biotech stocks.
A laboratory technician researching a sample of cells in a biotechnology laboratory.
Our Methodology
For our methodology, we looked up biotech stocks with a PE ratio below 18 and a market cap over 300 million and then ranked these stocks in ascending order based on their P/E ratios as of February 4th, 2025.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
Here is our list of the 10 cheap biotech stocks to invest in now.
10. Halozyme Therapeutics, Inc. (NASDAQ:HALO)
P/E Ratio: 19.08
Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a biopharmaceutical company focused on innovative drug delivery technologies, primarily through its Enhaze platform. This technology, based on the rHuPH20 enzyme, enables the subcutaneous administration of drugs typically delivered intravenously by improving absorption and dispersion.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) continues to solidify its position as an attractive biotech stock for investors seeking growth potential. For those looking for cheap biotech stocks to buy, Halozyme presents a compelling opportunity given its strong financial performance and innovative drug delivery technology. In its Q3 2024 financial report, the company showcased impressive growth with total revenues rising 34% to a record $290 million. Royalty revenue grew 36% to $155 million, both marking new highs for the company. Additionally, earnings per share (EPS) surpassed expectations at $1.27 compared to the anticipated $0.98. Halozyme Therapeutics, Inc. (NASDAQ:HALO) has raised its full-year guidance, now projecting total revenue growth between 17% and 23% and adjusted EBITDA growth between 40% and 47%.
The company’s growth is driven by the success and adoption of its Enhanze drug delivery technology, which has propelled key product sales. Darzalex Subcutaneous sales increased by 23% to $3 billion in a single quarter, while Phesgo experienced a 58% rise in sales, reaching CHF 1.2 billion in the first nine months of 2024. Analysts predict Phesgo could become a $3.5 billion brand by 2028. Additionally, Tecentriq Hybreza, newly approved in the U.S. for all adult IV indications, is expected to generate $5 billion in sales by 2028.
Halozyme Therapeutics, Inc. (NASDAQ:HALO)’s market strength is bolstered by recent FDA approvals for subcutaneous formulations of Tecentriq and Ocrevus using Enhanze technology. With Vyvgart Hytrulo projected to reach $5 billion in sales by 2028, the company is poised for continued growth and innovation.
As of Q3 2024, 23 hedge funds held stakes in the company as tracked by the Insider Monkey database. The largest stakeholder was Millennium Management with stakes worth $70.2 million.
9. Harmony Biosciences Holdings, Inc (NASDAQ:HRMY)
P/E Ratio: 18.65
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is a commercial-stage pharmaceutical company that develops and commercializes therapies to treat neurological disorders. Its product, Wakix, is a chemical that binds to H3 receptors and stimulates histamine transmission in the brain. For those with uncommon neurological conditions, the firm has one of the best pipelines.
As of right now, Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) has three orphan rare franchises that treat illnesses related to the central nervous system. With a $1 billion to $2 billion peak sales potential for each of its brands, investors are optimistic about the company. Eight assets are also part of the company’s pipeline, which spans 13 development programs, three of which are in crucial Phase 3 trials, and a fourth is at the beginning stage.
Thus, if successful, Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)’s present pipeline might generate over $3 billion in net revenue in the future. The corporation keeps up its business development efforts and is growing its pipeline. As of September 30, 2024, the company had around $505 million in cash, cash equivalents, and investments, putting it in a solid financial position to embark on more commercial development opportunities.
Hedge Fund Resource Center